Menu
No results found.
“Patience reduces risk more reliably than prediction.”
Weekly Share Price & Valuation Overview
Genmab A/S
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
- Growth + profitability: double-digit revenue and profit margins.
- Healthy operating margin (≥15%) indicates efficient core operations.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Double-digit profit margin (≥10%) supports robust bottom-line economics.
- ROE ≥15% reflects strong returns on shareholder equity.
- ROA ≥7% shows efficient use of assets.
- Revenue growth ≥10% indicates solid top-line momentum.
- Earnings growth ≥10% supports improving profitability trajectory.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
- Market Cap Total equity value of the company (share price × shares outstanding).
- DKK 107.73B
- Enterprise Value Operating value: market cap + total debt − cash.
- DKK 104.97B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- DKK 3.65B
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- DKK 3.45B
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- DKK 1.33B
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- DKK 57.79
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- 123.83
- Shares Outstanding
- 61.51M
- Float Shares
- 60.81M
- Implied Shares Outstanding
- 61.50M
- Operating Margin (TTM) Strong Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
38.92%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
36.40%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
94.54%
- Profit Margin (TTM) Solid Net income ÷ revenue over the last twelve months (reconciled when possible).
-
37.59%
- ROA Strong Return on assets: net income ÷ total assets.
-
13.26%
- ROE Excellent Return on equity: net income ÷ shareholder equity.
-
28.12%
- Revenue Growth Strong Year-over-year revenue growth.
-
18.70%
- Earnings Growth (YoY) Strong Year-over-year earnings growth.
-
73.20%
- Earnings Growth (QoQ) Quarter-over-quarter earnings growth.
-
65.50%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 6.20
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.03
- Total Cash Cash and equivalents.
- DKK 2.90B
- Total Debt Short + long-term interest-bearing debt.
- DKK 148.00M
- Net Debt Net Cash Total debt − cash (negative = net cash).
- DKK -2.75B
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- 0.11
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- DKK 1.13B
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- DKK 770.89M
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
31.11%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
21.14%
- Cash Conversion (OpCF/EBITDA)
- 0.85
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.